Nasus Pharma Ltd (NSRX) FinancialsNSRXNasus Pharma Ltd

In the context of the broader market, NSRX competes directly with industry leaders such as SDEV and HOWL. With a market capitalization of $42.39M, it holds a significant position in the sector. When comparing efficiency, NSRX's gross margin of N/A stands against SDEV's 100.00% and HOWL's 100.00%. Such benchmarking helps identify whether Nasus Pharma Ltd is trading at a premium or discount relative to its financial performance.

Nasus Pharma's financial performance shows a significant improvement in cash position, with $4.3 million reported as of December 31, 2025, up from $0.3 million in 2024, despite a net loss of $5.9 million in 2025.